Download PDF
CC BY-NC-ND 4.0 · Arq Neuropsiquiatr 2016; 74(11): 881-886
DOI: 10.1590/0004-282X20160139
ARTICLE

Polymorphism of the complement 5 gene is associated with large artery atherosclerosis stroke in Chinese patients

O polimorfismo do gene C5 do complemento está associado a acidentes vasculares cerebrais de grandes artérias com aterosclerose em pacientes chineses
Hui Wu
1   Minhang District Central Hospital, Department of Neurology, Shanghai, China;
,
Yingfeng Weng
1   Minhang District Central Hospital, Department of Neurology, Shanghai, China;
,
Lan Zheng
1   Minhang District Central Hospital, Department of Neurology, Shanghai, China;
,
Huanyin Li
1   Minhang District Central Hospital, Department of Neurology, Shanghai, China;
,
Qi Gong
1   Minhang District Central Hospital, Department of Neurology, Shanghai, China;
,
Yi Fu
2   Shanghai Jiao Tong University School of Medicine, Ruijin Hospital.
,
Jing Zhao
1   Minhang District Central Hospital, Department of Neurology, Shanghai, China;
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

ABSTRACT

The complement system has been confirmed to play an increasingly important role in ischemic stroke (IS). This study aimed to determine whether the single-nucleotide polymorphism of the complement 5 (C5) gene independently influences the occurrence, severity, and long-term outcome of IS in Chinese patients.

Methods C5 rs17611 genetic variants were investigated in 494 IS patients and 330 control individuals .Ischemic stroke was classified into subtypes and patients were assessed 90 days post-stroke with the modified Rankin Scale to determine stroke outcome.

Results The presence of C5 polymorphism was associated with the incidence of large artery atherosclerosis (LAA)-subtype IS (n =2 00; p = 0.031), which even persisted after adjustment for covariates (OR = 1.518; 95%CI = 1.093–2.018; p = 0.013). However, no association was found between genotypes and the severity and outcome of stroke (p = 0.978; p = 0.296).

Conclusions The C5 polymorphism might contribute to the risk of LAA-subtype IS independently of other known risk predictors.

RESUMO

Já se confirmou que o sistema do complemento exerce um papel cada vez mais importante nos acidentes vasculares cerebrais isquêmicos. Este estudo teve o objetivo de determinar se o polimorfismo de nucleotídeo único (SNP) do gene codificador do componente 5 (C5) influencia de forma independente a ocorrência, a severidade e o desfecho em longo prazo do acidente vascular cerebral isquêmico (AVCI) em pacientes chineses.

Métodos Variantes genéticas rs17611 do C5 foram investigadas em 494 pacientes com AVCI e em 330 indivíduos controles. O AVCI foi classificado em subtipos e os pacientes foram avaliados 90 dias após o acidente vascular, através da Escala Modificada de Rankin (mRS), para determinação do desfecho do acidente.

Resultados A presença de polimorfismo do C5 foi associada à incidência de AVCI do subtipo com aterosclerose de grandes artérias (AGA) (n = 200; p = 0,031), que persistiu mesmo após os ajustes de covariáveis (RP = 1,518; 95% IC = 1,093–2,018; p = 0,013). Entretanto, nenhuma associação foi observada entre os genótipos e a severidade ou o desfecho do acidente vascular (p = 0,978; p = 0,296).

Conclusões O polimorfismo do C5 pode contribuir para o risco de AVCI do tipo com AGA, independentemente de outros riscos preditores conhecidos.

genes - stroke
genes - acidente vascular cerebral

Support:

This work was supported by the National Natural Science Foundation of China (81572232), Shanghai Natural Science Foundation (13ZR1436600), Shanghai Health Bureau and the leading talents (20124266), Minhang District Natural Science Research Project (2015MHZ038)




Publication History

Received: 08 April 2016

Accepted: 26 July 2016

Article published online:
06 September 2023

© 2023. Academia Brasileira de Neurologia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Revinter Publicações Ltda.
Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil

 

  • References

  • 1 Cohen-Cory S, Kidane AH, Shirkey NJ, Marshak S. Brain-derived neurotrophic factor and the development of structural neuronal connectivity. Dev Neurobiol. 2010;70(5):271-88. doi:10.1002/dneu.20774
  • 2 Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med. 1999;340(2):115-26. doi:10.1056/NEJM199901143400207
  • 3 Warlow C, Sudlow C, Dennis M, Wardlaw J, Sandercock P. Stroke. Lancet. 2003;362(9391):1211-24. doi:10.1016/S0140-6736(03)14544-8
  • 4 Glass CK, Witztum JL. Atherosclerosis: the road ahead. Cell. 2001;104(4):503-16. doi:10.1016/S0092-8674(01)00238-0
  • 5 Niculescu F, Rus H. The role of complement activation in atherosclerosis’, Immunol Res. 2004;30(1):73-80. doi:10.1385/IR:30:1:073
  • 6 Greisenegger S, Zehetmayer S, Bauer P, Endler G, Ferrari J, Lang W et al. Polymorphisms in inflammatory genes and the risk of ischemic stroke and transient ischemic attack: results of a multilocus genotyping assay. Clin Chem. 2009;55(1):134-8. doi:10.1373/clinchem.2008.112151
  • 7 Seifert PS, Hansson GK. Complement receptors and regulatory proteins in human atherosclerotic lesions. Arteriosclerosis. 1989;9(6):802-11. doi:10.1161/01.ATV.9.6.802
  • 8 Széplaki G, Varga L, Füst G, Prohászka Z. Role of complement in the pathomechanism of atherosclerotic vascular diseases. Mol Immunol. 2009;46(14):2784-93. doi:10.1016/j.molimm.2009.04.028
  • 9 Stokowska A, Olsson S, Holmegaard L, Jood K, Blomstrand C, Jern C et al. Plasma C3 and C3a levels in cryptogenic and large-vessel disease stroke: associations with outcome. Cerebrovasc Dis. 2011;32(2):114-22. doi:10.1159/000328238
  • 10 Mocco J, Wilson DA, Komotar RJ, Sughrue ME, Coates K, Sacco RL et al. Alterations in plasma complement levels after human ischemic stroke. Neurosurgery. 2006;59(1):28-33. doi:10.1227/01.NEU.0000219221.14280.65
  • 11 Széplaki G, Szegedi R, Hirschberg K, Gombos T, Varga L, Karadi I et al. Strong complement activation after acute ischemic stroke is associated with unfavorable outcomes. Atherosclerosis. 2009;204(1):315-20. doi:10.1016/j.atherosclerosis.2008.07.044
  • 12 Hillebrandt S, Wasmuth HE, Weiskirchen R, Hellerbrand C, Keppeler H, Werth A et al. Complement factor 5 is a quantitative trait gene that modifies liver fibrogenesis in mice and humans. Nat Genet. 2005;37(8):835-43. doi:10.1038/ng1599
  • 13 Liu B, Wei L, Meyerle C, Tuo J, Sen HN, Li Z et al. Complement component C5a promotes expression of IL-22 and IL-17 from human T cells and its implication in age-related macular degeneration. J Transl Med. 2011;9(1):1-12. doi:10.1186/1479-5876-9-111
  • 14 Woehrl B, Brouwer MC, Murr C, Heckenberg SG, Baas F, Pfister HW et al. Complement component 5 contributes to poor disease outcome in humans and mice with pneumococcal meningitis. J Clin Invest. 2011;121(10):3943-53. doi:10.1172/JCI57522
  • 15 Giles JL, Choy E, Berg C, Morgan BP, Harris CL. Functional analysis of a complement polymorphism (rs17611) associated with rheumatoid arthritis. J Immunol. 2015;194(7):3029-34. doi:10.4049/jimmunol.1402956
  • 16 Traylor M, Farrall M, Holliday EG, Sudlow C, Hopewell JC, Cheng YC. Genetic risk factors for ischaemic stroke and its subtypes (the Metastroke collaboration): a meta-analysis of genome-wide association studies. Lancet Neurol. 2012;11(11): 951-62. doi:10.1016/S1474-4422(12)70234-X
  • 17 Berger K, Stögbauer F, Stoll M, Wellmann J, Huge A, Cheng S et al. The glu298asp polymorphism in the nitric oxide synthase 3 gene is associated with the risk of ischemic stroke in two large independent case-control studies. Hum Genet. 2007;121(2):169-78. doi:10.1007/s00439-006-0302-2
  • 18 Appelboom G, Piazza M, Hwang BY, Bruce S, Smith S, Bratt A et al. Complement Factor H Y402H polymorphism is associated with an increased risk of mortality after intracerebral hemorrhage. J Clin Neurosci. 2011;18(11):1439-43. doi:10.1016/j.jocn.2011.04.001
  • 19 Hoke M, Speidl W, Schillinger M, Minar E, Zehetmayer S, Schönherr M et al. Polymorphism of the complement 5 gene and cardiovascular outcome in patients with atherosclerosis. Eur J Clin Invest. 2012;42(9):921-6. doi:10.1111/j.1365-2362.2012.02669.x
  • 20 Adams HP Jr, Zoppo G, Alberts MJ, Bhatt DL, Brass L, Furlan A. Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: The American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Circulation. 2007;115(20): e478-534. doi:10.1161/CIRCULATIONAHA.107.181486
  • 21 Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL et al. Classification of subtype of acute ischemic stroke: definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke. 1993;24(1):35-41. doi:10.1161/01.STR.24.1.35
  • 22 Meyer BC, Hemmen TM, Jackson CM, Lyden PD. Modified National Institutes of Health Stroke Scale for use in stroke clinical trials: prospective reliability and validity. Stroke. 2002;33(5):1261-6. doi:10.1161/01.STR.0000015625.87603.A7
  • 23 Quinn TJ, McArthur K, Dawson J, Walters MR, Lees KR. Reliability of structured modified rankin scale assessment. Stroke. 2010;41(12):e602. doi:10.1161/STROKEAHA.110.590547